☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Cancers
Sanofi Entered into an Agreement with Merck to Conduct a P-II Study of THOR-707 in Sequenced Administration with MSD's KEYTRUDA (p...
October 30, 2020
AbbVie Licenses Lupin's MALT1 Inhibitor Program- for $977M
December 27, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.
